Sphingosine-1-Phosphate, Motor Severity, and Progression in Parkinson's Disease (MARK-PD)
| Autor: | Rainer H. Böger, Chi-Un Choe, Mirjam von Lucadou, Kristina Marmann, Sven Peine, Edzard Schwedhelm, Catrin Englisch, Susanne Lezius, Günter Daum, Louisa Niemann, Christian Gerloff |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
0301 basic medicine
medicine.medical_specialty Parkinson's disease Movement disorders Neuroprotection Gastroenterology Severity of Illness Index 03 medical and health sciences 0302 clinical medicine Interquartile range Sphingosine Tandem Mass Spectrometry Internal medicine medicine Humans business.industry Hazard ratio Montreal Cognitive Assessment Parkinson Disease medicine.disease Mental Status and Dementia Tests 030104 developmental biology Neurology Cohort Disease Progression Biomarker (medicine) Neurology (clinical) medicine.symptom Lysophospholipids business 030217 neurology & neurosurgery Chromatography Liquid |
| Zdroj: | Movement disorders : official journal of the Movement Disorder SocietyReferences. 36(9) |
| ISSN: | 1531-8257 |
| Popis: | Background Treatment with sphingosine-1-phosphate (S1P) agonists confers neuroprotective effects in animal models of Parkinson's disease (PD). Objectives We assessed the association of serum S1P levels with motor and cognitive symptoms in patients with PD. Methods S1P concentrations were analyzed with liquid chromatography-tandem mass spectrometry (LC-MS/MS) in serum of 196 PD patients and in 196 age- and sex-matched controls. Motor (Unified Parkinson's disease rating scale III [UPDRS III], Hoehn and Yahr) and cognitive (Montreal Cognitive Assessment [MoCA]) function were assessed at baseline. Follow-up data was available from 64 patients (median [interquartile range], 513 [381-677] days). Results S1P levels were lower in PD patients compared with controls, that is 1.75 (1.38-2.07) and 1.90 (1.59-2.18) μmol/L, respectively (P = 0.001). In PD patients, lower S1P concentrations were associated with higher UPDRS III scores and Hoehn and Yahr stage. In the follow-up cohort, S1P concentrations below the median were associated with faster motor decline (hazard ratio: 4.78 [95% CI, 1.98, 11.50]), but not with cognitive worsening. Conclusions Our observations reveal an association of S1P with PD. © 2021 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text